## JAPAC ADVISORY BOARD BIOSIMILARS MEETING REPORT

Intercontinental Seoul Coex Seoul, South Korea 24 November 2013

## JAPAC Biotherapeutics Advisory Board Objectives

- The JAPAC Advisory Board on Biosimilars brought together physicians from Asia Pacific countries across different specialties to provide expert opinions on the use of biosimilars.
- Topics discussed and feedback obtained included:
  - Regulatory approval
  - Nomenclature
  - Pharmacovigilance
  - Indication extrapolation
  - Education programs
- Assessment of impact of biosimilars on treatment approaches

## JAPAC Advisory Board Participant Advisors:

Tang Ching Lau Singapore

Khoon Lin Ling
Singapore

Masayoshi Harigai
Japan

Kazuhiko Yamamoto Japan

Yashiki Takura
Japan

David Wilking Nicholls Australia

Howard Lee
South Korea

Daniel Wai Tho Ching
New Zealand

Rong Mu
China

Lau Ing Soo Malaysia

Ping Nigh Hsu
Taiwan

## **Executive summary**

- The advisory board members suggested that both clinical efficacy and safety of biosimilars demonstrated in head-to-head comparative studies with the innovative product would be important considerations for clinical use.
- Local clinical data on biosimilars would also be necessary due to the differences in environmental and genetic factors among different countries.
- Most members did not totally agree with indication extrapolation based on mechanism of action and clinical data in the most sensitive population. The mechanism of action of TNF blockade is not fully understood across all indications.
- Safety profiles and the development of anti-drug antibodies in different disease conditions are the major concerns when extrapolating to a different indication.
- In most countries, both generic and brand names are used for prescription. Most members suggested that a unique naming system is required for biosimilars for easier tracking and adverse event reporting.